Pharm Sci Advisory Committee Revisiting Controversial Topics
This article was originally published in The Pink Sheet Daily
FDA's Pharmaceutical Science and Clinical Pharmacology expert panel will try to make strides in the regulatory minefields of bioequivalence and transdermal drug delivery systems.
You may also be interested in...
FDA expedited approval of Teva's ANDA fentanyl transdermal system after a shortage of fentanyl patches threatened patient access.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.